ZA989138B - Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics - Google Patents
Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesicsInfo
- Publication number
- ZA989138B ZA989138B ZA989138A ZA989138A ZA989138B ZA 989138 B ZA989138 B ZA 989138B ZA 989138 A ZA989138 A ZA 989138A ZA 989138 A ZA989138 A ZA 989138A ZA 989138 B ZA989138 B ZA 989138B
- Authority
- ZA
- South Africa
- Prior art keywords
- galactose
- pain
- agents
- analgesics
- conjugates
- Prior art date
Links
- 241001112695 Clostridiales Species 0.000 title 1
- 102000004856 Lectins Human genes 0.000 title 1
- 108090001090 Lectins Proteins 0.000 title 1
- 229940035676 analgesics Drugs 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 title 1
- 229930182830 galactose Natural products 0.000 title 1
- 239000002523 lectin Substances 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010055044 Tetanus Toxin Proteins 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 102000007563 Galectins Human genes 0.000 abstract 1
- 108010046569 Galectins Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721189.0A GB9721189D0 (en) | 1997-10-08 | 1997-10-08 | Analgesic conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA989138B true ZA989138B (en) | 1999-05-27 |
Family
ID=10820129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA989138A ZA989138B (en) | 1997-10-08 | 1998-10-07 | Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7052702B1 (xx) |
| EP (1) | EP0996468B1 (xx) |
| JP (1) | JP4629225B2 (xx) |
| AT (1) | ATE240747T1 (xx) |
| AU (1) | AU741456B2 (xx) |
| CA (1) | CA2306350C (xx) |
| DE (1) | DE69814858T2 (xx) |
| DK (1) | DK0996468T3 (xx) |
| ES (1) | ES2198750T3 (xx) |
| GB (1) | GB9721189D0 (xx) |
| PT (1) | PT996468E (xx) |
| WO (1) | WO1999017806A1 (xx) |
| ZA (1) | ZA989138B (xx) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| GB9907429D0 (en) * | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| WO2001014570A1 (en) * | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
| US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| EP1234043B1 (en) * | 1999-12-02 | 2004-03-10 | Health Protection Agency | Constructs for delivery of therapeutic agents to neuronal cells |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| AU4904101A (en) * | 1999-12-08 | 2001-07-09 | Fluoro Probe, Inc. | Method for relieving pain associated with an internal disease site |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6641820B1 (en) * | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| JP2004521067A (ja) * | 2000-06-28 | 2004-07-15 | サンダース，イラ | 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法 |
| DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| GB0108332D0 (en) * | 2001-04-03 | 2001-05-23 | Univ Durham | Lectin directed prodrug delivery system |
| US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
| US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| GB0213383D0 (en) * | 2002-06-11 | 2002-07-24 | Cambridge Biotechnology Ltd | Therapeutic conditions |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| EP1784420B1 (en) * | 2004-09-01 | 2008-12-03 | Allergan, Inc. | Degradable clostridial toxins |
| US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| CN101918021A (zh) * | 2007-10-23 | 2010-12-15 | 阿勒根公司 | 使用经修饰的梭菌毒素治疗泌尿生殖系统神经疾病的方法 |
| WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| BR112014029585A2 (pt) | 2012-05-30 | 2017-07-25 | Harvard College | neurotoxina botulínica engendrada |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| BR112015003591B1 (pt) | 2012-11-21 | 2022-02-01 | Ipsen Bioinnovation Limited | Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| EP3822286A1 (en) | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| CN115925835A (zh) | 2015-03-26 | 2023-04-07 | 哈佛大学校长及研究员协会 | 工程改造的肉毒杆菌神经毒素 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| WO2018039506A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| PL3529616T3 (pl) | 2016-10-20 | 2024-03-18 | President And Fellows Of Harvard College | Testy in vitro i komórkowe do pomiaru aktywności neurotoksyn botulinowych |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
| US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| JP7186228B2 (ja) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | 非細胞毒性プロテアーゼの注入を案内するための超音波の使用 |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| JP2024513191A (ja) | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US4873346A (en) | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
| CA2071969A1 (en) | 1989-12-22 | 1991-06-23 | John R. Murphy | Hybrid molecules having translocation region and cell-binding region |
| WO1992015327A1 (en) | 1991-03-08 | 1992-09-17 | Protein Design Labs, Inc. | Recombinant double chain immunotoxins |
| WO1993004191A1 (en) | 1991-08-15 | 1993-03-04 | Neorx Corporation | Noncytolytic toxin conjugates |
| US5433946A (en) | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| DE4242902A1 (de) | 1992-12-18 | 1994-06-23 | Madaus Ag | Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie |
| WO1994028923A1 (en) | 1993-06-10 | 1994-12-22 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| AU688452B2 (en) | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
| JP3497554B2 (ja) | 1994-03-25 | 2004-02-16 | 日本臓器製薬株式会社 | 新規プリン誘導体及びその薬学的に許容される塩 |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| DK0760681T3 (da) * | 1994-05-31 | 2000-03-27 | Allergan Inc | Modifikation af clostridielle toksiner til anvendelse som transportproteiner |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| AU709586B2 (en) | 1994-10-24 | 1999-09-02 | Ophidian Pharmaceuticals, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
| US5721207A (en) * | 1995-04-18 | 1998-02-24 | Innapharma, Inc. | Method for treatment of pain |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| WO1997013410A1 (en) | 1995-10-13 | 1997-04-17 | Boston Medical Center Corporation | Hybrid molecules containing amidated polypeptide binding ligands |
| WO1997018790A2 (en) * | 1995-11-22 | 1997-05-29 | The Research And Development Institute, Inc. | Therapeutic and diagnostic agents for the treatment of microbial infections |
| US5760149A (en) | 1996-08-23 | 1998-06-02 | Elf Atochem North America, Inc. | Poly(monoperoxycarbonates) |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| EP1105153A4 (en) | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
| DE19735105A1 (de) | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| PL201879B1 (pl) | 1998-05-13 | 2009-05-29 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Białko hybrydowe i jego zastosowanie |
| IL140893A0 (en) | 1998-07-22 | 2002-02-10 | Osprey Pharmaceuticals Ltd | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| GB9824282D0 (en) | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
-
1997
- 1997-10-08 GB GBGB9721189.0A patent/GB9721189D0/en not_active Ceased
-
1998
- 1998-10-07 AU AU93574/98A patent/AU741456B2/en not_active Ceased
- 1998-10-07 EP EP98946571A patent/EP0996468B1/en not_active Expired - Lifetime
- 1998-10-07 WO PCT/GB1998/003001 patent/WO1999017806A1/en active IP Right Grant
- 1998-10-07 DK DK98946571T patent/DK0996468T3/da active
- 1998-10-07 ZA ZA989138A patent/ZA989138B/xx unknown
- 1998-10-07 JP JP2000514674A patent/JP4629225B2/ja not_active Expired - Fee Related
- 1998-10-07 PT PT98946571T patent/PT996468E/pt unknown
- 1998-10-07 US US09/529,130 patent/US7052702B1/en not_active Expired - Fee Related
- 1998-10-07 CA CA002306350A patent/CA2306350C/en not_active Expired - Fee Related
- 1998-10-07 AT AT98946571T patent/ATE240747T1/de not_active IP Right Cessation
- 1998-10-07 ES ES98946571T patent/ES2198750T3/es not_active Expired - Lifetime
- 1998-10-07 DE DE69814858T patent/DE69814858T2/de not_active Expired - Lifetime
-
2005
- 2005-10-25 US US11/257,500 patent/US7452543B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7052702B1 (en) | 2006-05-30 |
| ATE240747T1 (de) | 2003-06-15 |
| GB9721189D0 (en) | 1997-12-03 |
| ES2198750T3 (es) | 2004-02-01 |
| EP0996468B1 (en) | 2003-05-21 |
| DK0996468T3 (da) | 2003-09-15 |
| CA2306350A1 (en) | 1999-04-15 |
| DE69814858T2 (de) | 2004-03-11 |
| AU9357498A (en) | 1999-04-27 |
| EP0996468A1 (en) | 2000-05-03 |
| CA2306350C (en) | 2008-09-02 |
| PT996468E (pt) | 2003-09-30 |
| WO1999017806A1 (en) | 1999-04-15 |
| DE69814858D1 (de) | 2003-06-26 |
| US7452543B2 (en) | 2008-11-18 |
| JP4629225B2 (ja) | 2011-02-09 |
| JP2001518522A (ja) | 2001-10-16 |
| AU741456B2 (en) | 2001-11-29 |
| US20060121056A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA989138B (en) | Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics | |
| MXPA03000576A (es) | Motivo a base de leucina y neurotoxinas clostridial. | |
| AU1225099A (en) | Protease variants and compositions | |
| PL323006A1 (en) | Derivatives of toxin clostridium capable to modify peripheral functions of afferent sensory fibres | |
| TR199701705T1 (xx) | Trigliserid ya�lar�n i�lenmesinde hareketsiz enzim ve kullan�m�. | |
| FI963861A (fi) | Alkalinen Bacillus-amylaasi | |
| DK0832250T3 (da) | Mutant alfa-amylase | |
| WO1999029876A3 (en) | Mutant bacillus licheniformis alpha-amylase | |
| WO2001077951A8 (en) | System and methods for group retirement plan administration | |
| NZ507874A (en) | Dressing with one or more elastic sections and adhesive on one side | |
| AU7645100A (en) | Wound care device | |
| BG103977A (en) | Low molecular rotamase enzymic activity inhibitors | |
| ATE328110T1 (de) | Chromogenes medium zum nachweis von staphylococcus aureus | |
| CA2505930A1 (en) | Use of botulinum toxin in the preparation of a pharmaceutical composition for treating urinary retention | |
| PT1311504E (pt) | Tetrazolil-fenil-acetamidas activadoras da glucoquinase | |
| AU2624095A (en) | Toxin assay | |
| ES2149982T3 (es) | Acidos naftalenoboronicos. | |
| DE69435307D1 (de) | Bazillus Thuringiensis und dessen insektizide Proteine | |
| WO2000064405A3 (en) | Treating hair by targeting enzymes | |
| BR9604825A (pt) | Citostáticos modificados por carboidratos | |
| PT1234043E (pt) | Construcoes para a entrega de agentes terapeuticos a celulas neuronais | |
| AU2003295769A1 (en) | Treatment of mammalian reaction to ige interactions | |
| AU2002216621A1 (en) | Optical isolator with low insertion loss and minimized polarization mode dispersion | |
| AU7083096A (en) | Connector for sling devices | |
| DK177791A (da) | Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym |